Business Context and Reporting Period
This Form 8-K is filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc., as indicated in the metadata request) on August 1, 2019. The report serves to announce the company's financial results for the quarter ended June 30, 2019. The registrant is an emerging growth company incorporated in Delaware, with its common stock trading on The Nasdaq Stock Market under the symbol GLYC.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K. Consequently, no specific financial metrics can be extracted from the provided source text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It directs readers to the attached press release (Exhibit 99.1) for the announcement of financial results and recent operational highlights.
Guidance, Outlook, and Risks
The document includes a standard disclaimer in accordance with General Instruction B.2 of Form 8-K. It states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that section. Specific guidance, outlook, management commentary, or risk factors are not detailed in the text of this report.
Investor Verification Checklist
- Verify the correct registrant name is GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from the 8-K body text.
- Confirm the reporting period is the quarter ended June 30, 2019.
- Note that the financial data in this filing is not deemed "filed" under Section 18 of the Exchange Act.